A meta-analysis of BRF2 as a prognostic biomarker in invasive breast carcinoma

BMC Cancer

Stephanie Cabarcas-Petroski¹  Patricio I. Meneses²  Laura Schramm³ 

[1] Biology Department, Pennsylvania State University, Beaver Campus, Monaca, PA, USA;Department of Biological Sciences, Fordham University, Bronx, NY, USA;Department of Biological Sciences, St. John’s University, Queens, NY, USA;

关键词: RNA polymerase III;    TFIIIB;    BRF2;    Cancer;    Prognostic marker;   

DOI  :  10.1186/s12885-020-07569-8

来源: Springer

【 摘 要 】

BackgroundDeregulation of the RNA polymerase III specific TFIIIB subunit BRF2 occurs in subtypes of human cancers. However, correlations between BRF2 alterations and clinical outcomes in breast cancer are limited. We conducted this review to analyze BRF2 alterations in genomic data sets housed in Oncomine and cBioPortal to identify potential correlations between BRF2 alterations and clinical outcomes.MethodsThe authors queried both Oncomine and cBioPortal for alterations in BRF2 in human cancers and performed meta-analyses identifying significant correlations between BRF2 and clinical outcomes in invasive breast cancer (IBC).ResultsA meta cancer outlier profile analysis (COPA) of 715 data sets (86,733 samples) in Oncomine identified BRF2 as overexpressed in 60% of breast cancer data sets. COPA scores in IBC data sets (3594 patients) are comparable for HER2 (24.211, median gene rank 60) and BRF2 (29.656, median gene rank 36.5). Overall survival in IBC patients with BRF2 alterations (21%) is significantly decreased (p = 9.332e-3). IBC patients with BRF2 alterations aged 46 to 50 have a significantly poor survival outcome (p = 7.093e-3). Strikingly, in metastatic breast cancer, BRF2 is altered in 33% of women aged 45–50. BRF2 deletions are predominant in this age group.ConclusionThis study suggests BRF2 may be an prognostic biomarker in invasive breast carcinoma.

【 授权许可】

CC BY